Cover Image

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects

Su-jin Rhee,1,* YoonJung Choi,1,* SeungHwan Lee,1,2 Jaeseong Oh,1 Sung-Jin Kim,3 Seo Hyun Yoon,1 Joo-Youn Cho,1 Kyung-Sang Yu1 1Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; 2Clinical...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rhee SJ (Author), Choi Y (Author), Lee S (Author), Oh J (Author), Kim SJ (Author), Yoon SH (Author), Cho JY (Author), Yu KS (Author)
Format:	Book
Published:	Dove Medical Press, 2016-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
by: Gu N, et al.
Published: (2014)

Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
by: Rhee SJ, et al.
Published: (2016)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
by: Hwang I, et al.
Published: (2020)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers
by: Yoon S, et al.
Published: (2017)

Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers
by: Shin Y, et al.
Published: (2022)

Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
by: Dasohm Kim, et al.
Published: (2023)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
by: Jiang X, et al.
Published: (2023)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
by: Chenkai Cui, et al.
Published: (2022)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
by: Jeon I, et al.
Published: (2021)

Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus
by: Fan YJ, et al.
Published: (2015)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
by: Christina S. Kwon, et al.
Published: (2018)

A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
by: Park SI, et al.
Published: (2015)

Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
by: Hong T, et al.
Published: (2015)

The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers
by: Guojing Liu, et al.
Published: (2016)

Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects
by: Moon SJ, et al.
Published: (2019)

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
by: Cha YJ, et al.
Published: (2014)

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
by: Kim CO, et al.
Published: (2016)

Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
by: Yoon S, et al.
Published: (2015)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
by: Shoombuatong W, et al.
Published: (2015)

Effects of vancomycin‐induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects
by: Eunwoo Kim, et al.
Published: (2021)

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects
by: Kim CH, et al.
Published: (2017)

Pharmacokinetics of a Fixed-Dose Combination of Teneligliptin Hydrochloride Hydrate and Modified-Release Metformin Under Fasting and Fed Conditions in Healthy Subjects
by: Goak IS, et al.
Published: (2022)

The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics
by: Jiagen Wen, et al.
Published: (2019)

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan
by: Gu N, et al.
Published: (2016)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
by: Yingying Hu, et al.
Published: (2023)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
by: Haijing Yang, et al.
Published: (2022)

Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects
by: Shin D, et al.
Published: (2017)

Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
by: Jang K, et al.
Published: (2017)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
by: Choi C, et al.
Published: (2018)

Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects
by: Yu-Jeong Son, et al.
Published: (2023)

Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects
by: Hwang S, et al.
Published: (2021)

Dipeptidyl Peptidase IV Inhibitory Activity of Berberine and Mangiferin: An In Silico Approach
by: Ipseeta Ray Mohanty, et al.
Published: (2017)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid,
by: Agoritsa Gravani, et al.
Published: (2022)

Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV
by: Rohani, et al.
Published: (2023)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018)

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to
by: Shian-Ren Lin, et al.
Published: (2019)

Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects
by: Patrick C. Dolder, et al.
Published: (2017)

Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects
by: Isabelle Zenklusen, et al.
Published: (2024)

The Effect of Compression Pressure on the First Layer Surface Roughness and Delamination of Metformin and Evogliptin Bilayer and Trilayer Tablets
by: Sun Ho Kim, et al.
Published: (2023)

A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes
by: Sibhghatulla Shaikh, et al.
Published: (2021)